1171891-35-2

Usage

Uses

Used in Organic Synthesis:
5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-ol is used as a reagent in Suzuki-Miyaura cross-coupling reactions for the formation of carbon-carbon bonds. Its presence as a ligand in transition metal-catalyzed transformations allows for the construction of complex molecules, making it a valuable tool in organic chemistry.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-ol is used as a key intermediate for the synthesis of various drug candidates. Its unique structure and reactivity enable the development of novel therapeutic agents with potential applications in treating various diseases.
Used in Agrochemical Research:
Similarly, in agrochemical research, 5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-ol is utilized as a building block for the synthesis of new agrochemicals, such as pesticides and herbicides. Its versatility in organic synthesis contributes to the development of innovative and effective products for agricultural applications.

Upstream product

• 74115-13-2 5-bromopyridine-3-ol 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 1605327-44-3 (S)-2-(1-((6-amino-5-(5-hydroxypyridin-3-yl)pyrimidin-4-yl)amino)ethyl)-3-phenylpyrrolo[2,1-f][1,2,4]triazin-4(3H)-one 

Relevant academic research and scientific papers

PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS

New pyrrolotriazinone derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks).

Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6- pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease

4-Acetylamino-2-(3,5-dimethylpyrazol-1-yl)-pyrimidines bearing substituted pyridyl groups as C-6 substituents were prepared as selective adenosine hA 2A receptor antagonists for the treatment of Parkinson's disease. The 5-methoxy-3-pyridyl derivative 6g (hA2A Ki 2.3 nM, hA1 Ki 190 nM) was orally active at 3 mg/kg in a rat HIC model but exposure was poor in nonrodent species, presumably due to poor aqueous solubility. Follow-on compound 16a (hA2A Ki 0.83 nM, hA1 Ki 130 nM), bearing a 6-(morpholin-4-yl)-2-pyridyl substituent at C-6, had improved solubility and was orally efficacious (3 mg/kg, HIC) but showed time-dependent cytochrome P450 3A4 inhibition, possibly related to morpholine ring metabolism. Compound 16j (hA2A Ki 0.44 nM, hA1 Ki 80 nM), bearing a 6-(4-methoxypiperidin-1-yl)- 2-pyridyl substituent at C-6, was sparingly soluble but had good oral exposure in rodent and nonrodent species, had no cytochrome P450 or human ether-a-go-go related gene channel issues, and was orally efficacious at 1 mg/kg in HIC and at 3 mg/kg for potentiation of L-dopa-induced contralateral rotations in 6-hydroxydopamine-lesioned rats.